PMID- 30075584
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 31
DP  - 2018 Aug
TI  - Direct costs associated with adverse events of systemic therapies for advanced 
      melanoma: Systematic literature review.
PG  - e11736
LID - 10.1097/MD.0000000000011736 [doi]
LID - e11736
AB  - BACKGROUND: Treatments for advanced melanoma are associated with different 
      adverse events (AEs), which may be costly to manage. This study aimed to evaluate 
      direct costs associated with managing treatment-related AEs for advanced melanoma 
      through a systematic literature review. METHODS: Systematic searches were 
      conducted of the PubMed, Embase, Cochrane, BIOSIS, and EconLit medical literature 
      databases to identify studies providing estimates of direct costs and health care 
      resource utilization for the management of AEs of melanoma treatments, published 
      between January 1, 2007, and February 23, 2017. Gray literature searches also 
      were conducted. Studies reporting direct costs for patients with advanced 
      melanoma that were published in English between 2007 and 2017 were eligible. 
      Studies were systematically screened in 2 phases by 2 independent reviewers. 
      Study design details and data on direct costs by country were extracted. RESULTS: 
      Seven studies evaluating the cost of AEs in patients with advanced melanoma were 
      included; most estimated the costs for grade 3 or 4 events. In a United States 
      study, monthly AE costs constituted 36.9% of overall health care costs for 
      dacarbazine, 30.3% for paclitaxel, 9.2% for temozolomide, 6.4% for vemurafenib, 
      and 4.0% for ipilimumab. A multicountry study found the greatest cost per event 
      to be for grade 3 or 4 AEs associated with ipilimumab, including colitis (A$1471 
      [Australia]-&OV0556;3313 [France]) and diarrhea ( pound2836 [United Kingdom]), and 
      chemotherapy (neutropenia/leukopenia in Germany [&OV0556;1744] and Italy 
      [&OV0556;804]). Across studies, cost drivers for the most expensive AEs to manage 
      were requiring hospitalization or use of expensive outpatient medications and/or 
      procedures (eg, erythropoietin and blood transfusions for anemia). Some currently 
      available therapies were not available during the research period, and their 
      associated AEs are not reflected. Results may not be comparable across countries. 
      For some studies, resource-use estimates reflect practice patterns from a limited 
      number of centers, limiting generalizability. CONCLUSION: Costs for managing each 
      type of AE associated with the treatment of advanced melanoma are substantial. 
      Effective treatments with improved safety profiles may help reduce total AE 
      management costs.
FAU - Copley-Merriman, Catherine
AU  - Copley-Merriman C
AD  - Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI Merck & 
      Co, Inc, Kenilworth, NJ Health Economics, RTI Health Solutions, Research Triangle 
      Park, NC Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, 
      UK Division of Hematology - Medical Oncology, Jonsson Comprehensive Cancer 
      Center, University of California at Los Angeles, Los Angeles, CA.
FAU - Stevinson, Kendall
AU  - Stevinson K
FAU - Liu, Frank Xiaoqing
AU  - Liu FX
FAU - Wang, Jingshu
AU  - Wang J
FAU - Mauskopf, Josephine
AU  - Mauskopf J
FAU - Zimovetz, Evelina A
AU  - Zimovetz EA
FAU - Chmielowski, Bartosz
AU  - Chmielowski B
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Ipilimumab)
RN  - 0 (Sulfonamides)
RN  - 207SMY3FQT (Vemurafenib)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Dacarbazine/adverse effects/analogs & derivatives
MH  - Health Expenditures/*statistics & numerical data
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Indoles/adverse effects
MH  - Ipilimumab/adverse effects
MH  - Melanoma/*drug therapy
MH  - Paclitaxel/adverse effects
MH  - Sulfonamides/adverse effects
MH  - Temozolomide
MH  - Vemurafenib
PMC - PMC6081130
EDAT- 2018/08/05 06:00
MHDA- 2018/08/28 06:00
PMCR- 2018/08/03
CRDT- 2018/08/05 06:00
PHST- 2018/08/05 06:00 [entrez]
PHST- 2018/08/05 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2018/08/03 00:00 [pmc-release]
AID - 00005792-201808030-00094 [pii]
AID - MD-D-18-02276 [pii]
AID - 10.1097/MD.0000000000011736 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736.